Course Summary
The MSc in Biotherapeutics & Business educates students on the practical uses of molecular advances in the discovery of proteins and other biomolecular drug candidates and their development into biotherapeutics. It will provide you with a comprehensive understanding of the development of biotherapeutics, beginning with pre-clinical modelling and target identification together with antibody engineering, biochemical and biophysical characterisation, and development issues for bioprocessing.
College Link
Career Sectors
This course prepares you for working in the Career Sectors below. Follow the links to get a fuller understanding of the sectors you are preparing for.
Entry Requirements
Candidates must have obtained at least an upper Second Class Honours (2:1) Grade or equivalent in an honours BSc in Biotechnology, Biochemistry, Microbiology, Genetics, Neuroscience, Physiology, Pharmacology, Medicinal Chemistry or an equivalent qualification.
If English is not your native language, unless you have done your primary degree through English in an English speaking country, an English language qualification is required for all programmes. English Language qualifications include a minimum score of 550 (213 computer based) for Test of English as a Foreign Language (TOEFL), or 6.5 (with a score of 6 obtained in each category) for International English Language Testing System (IELTS). Other evidence of proficiency in English may be accepted such as the Cambridge Certificate. Tests used as evidence of language proficiency must have been completed within the last 12 months.
2 academic references will be required, at least one to be from a science faculty member.
Students meeting the programme’s academic entry requirements but not the English language requirements, may enter the programme upon successful completion of UCD’s Pre-Sessional or International Pre-Master’s Pathway programmes. Please see the following link for further information http://www.ucd.ie/alc/programmes/pathways/
These are the minimum entry requirements – additional criteria may be requested for some programmes.
You may be eligible for Recognition of Prior Learning (RPL), as UCD recognises formal, informal, and/or experiential learning. RPL may be awarded to gain Admission and/or credit exemptions on a programme. Please visit the UCD Registry RPL web page for further information. Any exceptions are also listed on this webpage. https://tinyurl.com/2ae2ffax
Application Details
The following entry routes are available:
MSc Biotherapeutics & Business FT (F103)
Duration 1 Years Attend Full Time
Deadline Rolling*
* Courses will remain open until such time as all places have been filled, therefore early application is advised
Next Intake: September 2025.
Fees
.MSc Biotherapeutics and Business (F103) Full Time
EU fee per year - € 16000
nonEU fee per year - € 29100
***Fees are subject to change
Tuition fee information is available on the UCD Fees website. Please note that UCD offers a number of graduate scholarships for full-time, self-funding international students, holding an offer of a place on a UCD graduate degree programme. For further information please see International Scholarships.
The Student
Career Interests
This course is typically suited for people with the following Career Interests. If these interests do not describe you, this course may prepare you for work you may not find satisfying.
Investigative
The Investigative person will usually find a particular area of science to be of interest. They are inclined toward intellectual and analytical activities and enjoy observation and theory. They may prefer thought to action, and enjoy the challenge of solving problems with sophiscticated technology. These types prefer mentally stimulating environments and often pay close attention to developments in their chosen field.
Career Progression
This graduate degree in Biotherapeutics & Business has been developed in consultation with employers and therefore will be recognised and valued by them. A key feature is the opportunity to carry out a business development plan, which will allow graduates to develop connections with prospective employers, thereby enhancing chances of employment on graduation.
Prospective employers include Abbott, Allergan, Amgen, Baxter Healthcare, Eli Lilly and Co., Dignity Sciences, GSK, Icon Clinical Research, ImmunoGen Inc., Janssen Pharmaceutical Ltd., Johnson & Johnson Ltd., MSD, Quintiles, Quest International, Sandoz and Seroba Life Sciences.